US Patent

US9278096 — Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity

Method of Use · Assigned to H Lundbeck AS · Expires 2032-03-21 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects new pharmaceutical uses of vortioxetine hydrobromide and its pharmaceutically acceptable salts.

USPTO Abstract

New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2436`	—	vortioxetine-hydrobromide
`U-2436`	—	vortioxetine-hydrobromide
`U-2436`	—	vortioxetine-hydrobromide
`U-2436`	—	vortioxetine-hydrobromide

Patent Metadata

Patent number: US9278096
Jurisdiction: US
Classification: Method of Use
Expires: 2032-03-21
Drug substance claim: No
Drug product claim: No
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.